Xantos Biomedicine AG and Cryptome Pharmaceuticals Ltd collaborate to validate cancer lead
Cryptome has developed the unique Cryptomics(TM) drug discovery platform that rapidly identifies bioactive fragments whose function is locked within larger protein molecules. The company calls these fragments crypteins, and Cryptomics(TM) provides a high throughput means of finding them. Crypteins have multiple advantages over small molecules and antibodies as therapeutic agents and Cryptome is building a pipeline of drug candidates based on its technology. Cryptome will use Cryptomics(TM) to validate one of Xantos' valuable angiogenic therapeutic leads. The financial terms of the agreement are not disclosed but involve cash and milestone payments to CRP. Intellectual property rights for new therapeutic candidates will be assigned to Xantos.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.